Get started
Author

Titus Watrin

Observed names: Titus Vatrin, Watrin, Titus Julius Maximilian
ORCID: 0009-0003-2665-9639
Observed ORCID: 0009-0003-2665-9639
OpenAlex ID: A5088047573
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
2021 · Sarah B. Reusing, Dan A. Vallera, et al. · Cancer Immunology Immunotherapy · 44
PDF
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
2023 · Athanasios Oikonomou, Luigia Valsecchi, et al. · Biochemical Pharmacology · 23
Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia
2024 · Fabian Fischer, Julian Schliehe-Diecks, et al. · Journal of Medicinal Chemistry · 12
Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma
2022 · Anne Schedel, Ulrike Anne Friedrich, et al. · International Journal of Molecular Sciences · 7
PDF
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening
2024 · Athanasios Oikonomou, Titus Watrin, et al. · Heliyon · 4
The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN)
2025 · Titus Watrin, Marc Seifert, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients
2025 · Paul Jäger, Benno Biermann, et al. · eJHaem · 1
The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance
2022 · Luigia Valsecchi, Simone Naso, et al. · Blood · 1
Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
2021 · Sarah B. Reusing, Dan A. Vallera, et al. · Cancer Immunology Immunotherapy · 1
PDF
Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation
2026 · Guido Kobbe, Titus Watrin, et al. · Frontiers in Immunology
PDF
Efficacy of the kinase inhibitor CHZ868 against JAK2 rearrangements in pediatric acute lymphoblastic leukemia
2026 · Manuel Quadri, Claudia Saitta, et al. · Haematologica
PDF
Impact of early tacrolimus exposure on outcomes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
2026 · Paul Jäger, Andreas Alexander Ralfs, et al. · Annals of Hematology
PDF
A novel metabolic role of Musashi-2 underlies glucocorticoid resistance in Acute Lymphoblastic Leukemia
2026 · Michela Bardini, Luigia Valsecchi, et al. · Research Square
Risk factors associated with prolonged treatment courses of chronic Hepatitis E
2025 · Alexander Killer, Elisa Hellendahl, et al.
P325: Applications of High-throughput Drug Screening as Drug Repurposing Strategy for Poor Outcome Subgroups of Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
2023 · Athanasios Oikonomou, Luigia Valsecchi, et al. · HemaSphere
Targeting Hyperactivated Lck in PAX5 Rearranged Pediatric B-Cell Precursors Acute Lymphoblastic Leukemia
2022 · Grazia Fazio, Manuel Quadri, et al. · Blood
3081 – Lck Drug Targeting in Pax5 Rearranged Cases in Poor Risk Childhood B-cell Precursors Acute Lymphoblastic Leukaemia
2022 · Grazia Fazio, Grazia Fazio, et al. · Experimental Hematology
Works count: 18
Citation count: 94
H-index: 4
I10-index: 3
Year
Topic
Type